Abstract
The effectiveness of antibiotic prophylaxis for recurrent urinary tract infections is being compromised as increasing numbers of uropathogens develop resistance to conventional antibiotics. Because one alternative to antibiotic therapy is immunization of susceptible patients to increase innate resistance, several different vaccines are currently being developed. Four of the vaccines contain a mixture of whole bacteria or an antigenic extract and are administered as a vaginal suppository or oral tablet. A parenteral route is being used in clinical trials of the Escherichia coli type 1 fimbrial adhesin and its chaperone protein. The safety of both the mucosal and parenteral vaccines has been demonstrated in phase 1 clinical trials. Phase 2 trials have shown the efficacy of a vaginal mucosal vaccine containing whole bacteria and an oral vaccine prepared from bacterial lysates. Further clinical trials will allow comparisons of the various vaccines and evaluation of their effectiveness relative to prophylactic antibiotic therapy.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
Ronald AR, Nicolle LE, Stamm E, et al.: Urinary tract infection in adults: research priorities and strategies. Int J Antimicrob Agents 2001, 17:343–348.
Gupta K, Sahm DF, Mayfield D, et al.: Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in women: a nationwide analysis. Clin Infect Dis 2001, 33:89–94.
Sahm DF, Thornsberry C, Mayfield DC, et al.: Multidrug-resistant urinary tract isolates of Escherichia coli: Prevalence and patient demographics in the United States in 2000. Antimicrob Agents Chemother 2001, 45:1402–1406.
Ogra PL, Faden H, Welliver RC: Vaccination strategies for mucosal immune responses. Clin Microbiol Rev 2001, 14:430–445.
Ruttgers H, Grischke E: Elevation of secretory IgA antibodies in the urinary tract by immunostimulation for the preoperative treatment and post-operative prevention of urinary tract infections. Urol Int 1987, 42:424–426.
Grischke EM, Ruttgers H: Treatment of bacterial infections of the female urinary tract by immunization of the patients. Urol Int 1987, 42:338–341.
Hopkins WJ, James LJ, Uehling DT, Balish E: Vaginal mucosal and parenteral immunization of mice with bacteria. J Urol 1991, 146:223–226.
Uehling DT, Hopkins WJ, James LJ, et al.: Vaginal immunization of monkeys against urinary tract infection with a multi-strain vaccine. J Urol 1994, 151:214–216.
Uehling DT, Hopkins WJ, Dahmer LA, et al.: Phase I clinical trial of vaginal mucosal immunization for recurrent urinary tract infection. J Urol 1994, 152:2308–2311.
Uehling DT, Hopkins WJ, Balish E, et al.: Vaginal mucosal immunization for recurrent urinary tract infection: Phase II clinical trial. J Urol 1997, 157:2049–2052. Describes phase 2 clinical trials of vaginal suppository immunization with Urovac®.
Uehling DT, Hopkins WJ, Beierle LM, et al.: Vaginal immunization for recurrent urinary tract infection: extended phase II clinical trial. J Infect Dis 2001, 183(Suppl 1):S81-S83.
Bessler WG, Kleine B, Martinez A, et al.: Biological activity of bacterial surface components: bacterial extracts and defined bacterial cell wall components as immunmodulators. Lung 1990, 168:707–715.
Sedelmeier E, Bessler WG: Biological activity of bacterial cell wall components: immunogenicity of the bacterial extract OM-89. Immunopharmacology 1995, 29:29–36.
Huber M, Baier W, Serr A, et al.: Immunogenicity of an E. coli extract after oral or intraperitoneal administration: induction of antibodies against pathogenic bacterial strains. Int J Immunopharmacol 2000, 22:57–68.
Huber M, Krauter K, Winkelmann G, et al.: Immunostimulation by bacterial components: II. Efficacy studies and metaanalysis of the bacterial extract OM-89. Int J Immunopharmacol 2000, 22:1103–1111. Summary of Uro-Vaxom® animal and human studies and metaanalysis of clinical trials.
Wybran J, Libin M, Schandene L: Enhancement of cytokine production and natural killer activity by an Escherichia coli extract. Immunopharmacol Immunotoxicol 1989, 11:17–32.
Koukalova D, Reif R, Hajek V, et al.: Urvakol vaccine in immunomodulation of recurrent urinary tract infections. Bratisl Lek Listy 1999, 100:246–251.
Nenkov P: Overview on the clinical studies with Urostim immunostimulator against urogenital infections. Adv Exp Med Biol 2000, 485:325–329.
Roberts JA, Hardaway K, Kaack B: Prevention of pyelonephritis by immunization with p-fimbriae. J Urol 1984, 131:602–607.
Connell H, Agace W, Klemm P, et al.: Type 1 fimbrial expression enhances Escherichia coli virulence for the urinary tract. Proc Natl Acad Sci U S A 1996, 93:9827–9832.
Langermann S, Ballou WR: Vaccination using the FimCH complex as a strategy to prevent Escherichia coli urinary tract infections. J Infect Dis 2001, 183(Suppl 1):S84-S86.
Langermann S, Palaszynski S, Barnhart M, et al.: Prevention of mucosal Escherichia coli infection by FimH adhesin-based systemic vaccination. Science 1997, 276:607–611. Contains studies of parenteral immunization of mice with type 1 adhesin of E. coli.
Langermann S, Mollby R, Burlein J, et al.: Vaccination with FimH adhesin protects cynomolgus monkeys from colonization and infection by uropathogenic Escherichia coli. J Infect Dis 2000, 181:774–778.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hopkins, W.J., Uehling, D.T. Vaccine development for the prevention of urinary tract infections. Curr Infect Dis Rep 4, 509–513 (2002). https://doi.org/10.1007/s11908-002-0037-8
Issue Date:
DOI: https://doi.org/10.1007/s11908-002-0037-8